PANCREAS

PANCREAS Journal

publication venue for

Effects of Second-Hand Smoke on Pancreatitis in Children. 48:706-710. 2019
A Single Fasting Plasma 5-HIAA Value Correlates With 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs). 42:405-410. 2013
Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma). 42:348-352. 2013
Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period. 40:987-994. 2011
Validation of Neurokinin A Assays in the United States and Europe. 40:1000-1005. 2011
Brain-derived neurotrophic factor is upregulated in rats with chronic pancreatitis and mediates pain behavior.. 40:551-6. 2011
A Prospective Trial on the Effect of Body Mass Index and Sex on Plasma Octreotide Levels in Patients Undergoing Long-Term Octreotide LAR Therapy. 39:964-966. 2010
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor. 39:713-734. 2010
Neuroendocrine Tumors A Critical Appraisal of Management Strategies. 39:801-818. 2010
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer. 39:775-783. 2010
Development of a Highly Sensitive and Specific Carboxy-Terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior. 39:611-616. 2010
Pdx-1 Regulation of the INGAP Promoter Involves Sequestration of NeuroD Into a Non-DNA-Binding Complex. 39:64-70. 2010
Pdx-1 Regulation of the INGAP Promoter Involves Sequestration of NeuroD Into a Non-DNA-Binding Complex. 39:64-70. 2010
Development of the Norfolk Quality of Life Tool for Assessing Patients With Neuroendocrine Tumors. 38:E87-E95. 2009
The reg family member INGAP is a marker of endocrine patterning in the embryonic pancreas. 36:1-9. 2008
The Reg family member INGAP is a marker of endocrine patterning in the embryonic pancreas.. 36:1-9. 2008
Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs. 34:103-111. 2007
Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs.. 34:103-11. 2007
Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors - Lack of correlation between absolute chromogranin A levels and symptom frequency. 33:250-254. 2006
Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. 31:392-400. 2005
Biochemical Testing for Neuroendocrine Tumors (vol 38, pg 876, 2009) 2010
Radioligand Theranostics in the Management of Neuroendocrine Tumors 2020
BUN Change From Admission and Levels at 24-48 Hours are Significant Predictors of Severity in Pediatric Acute Pancreatitis 2019
Lanreotide for the Prolonged Control of Carcinoid Syndrome (CS) in Somatostatin Analog (SSA)-Naive or -Experienced Patients 2019
Lanreotide for the Prolonged Control of Carcinoid Syndrome (CS) in Somatostatin Analog (SSA)-Naive or -Experienced Patients 2019
5-Hydroxyindoleacetic Acid (5-HIAA) and Chromogranin A (CgA) as Biomarkers Secreted by Neuroendocrine Tumors (NETs): A Pooled Analysis of the ELECT and CLARINET Studies 2018
Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot 2018
Elevated Levels of 5-HIAA and CgA in Patients With Pancreatic Neuroendocrine Tumors (PanNETs): Analyses From the CLARINET Study 2018
Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study 2018
Safety and Tolerability of Lanreotide Autogel/Depot in Patients With Neuroendocrine Tumors: Pooled Analysis of Clinical Studies 2018
Somatostatin Analog Usage in Neuroendocrine Tumors: A Retrospective Database Analysis 2018
Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases 2017
Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension 2017
Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy 2016
A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs) 2013
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) 2012
Sunitinib for Treatment of Pancreatic Neuroendocrine Tumors: Patient-Reported Outcomes and Efficacy Across Patient Subgroups in a Phase III Trial 2011
A Prospective Trial on the Effect of Body Mass Index and Gender on Plasma Octreotide Levels in Patients Undergoing Long Term Therapy With Octreotide LAR 2010
Development of a Highly Sensitive and Specific Carboxy-Terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior 2010
Relationship Between Quality of Life and Health-Related Measures Including Symptoms, Biochemical Markers And Tumor Burden 2010
Early Detection of Sporadic Pancreatic Cancer Summative Review 2015
Biochemical Testing for Neuroendocrine Tumors 2009

International Standard Serial Number (ISSN)

0885-3177

Electronic International Standard Serial Number (EISSN)

1536-4828